Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Thursday Julv 1

Poster Exiiin Thursday0 Iu7v-i

ThPeB7196 Factors predicting the uptake of HAART in
primary HIV infection (PHI)
K Porter A S Walker, on behalf of CASCADE
Collaboration (United Kingdom)
ThPeB7197 Renal abnormalities associated with human
immunodeficiency virus infection among police
officers in Dar-es-Salaam, Tanzania
M Y janabi', S Chale', P Magao', R ]ossiah',
M Bakari', E Lyamuya', F Mugusi', A Swai',
FMhalu', K Pallangyo', N Pallangyo',
G Biberfeld2, E Sandstrom2 1Tanzania; 2Sweden)
ThPeB7198 NNRTI based therapy for the treatment of acute
and early HIV-1 infection. Clinical issues and
immunological studies
SD Portsmouth N Imami, A Pires, ] Hand, F Gotch,
M Nelson, B G Gazzard (United Kingdom)
ThPeB7199 The burden of mental illness in an urban HIV
population
M E Theodore, H Wolfe, V Sharp (United States)
ThPeB7200 No greater immune recovery with treatment of
acute primary HIV infection (PHI)
T P T Ramacciotti, DE Smith, P Cunningham,
DA Cooper, ] M Kaldor (Australia)
ThPeB7201ol Immunologic and virologic markers during follow
up of initial versus delayed therapy versus no
therapy during primary HIV infection (PHI)
T P T Ramacciotti, DE Smith, ]] Zaunders,
DA Cooper, ] M Kaldor (Australia)
ThPeB72o2 The national HIV telephone consultation service
(Warmline): trends in caller characteristics and
questions about antiretroviral therapy and PCP,
1991 tO 2001
] ]Myers, S Sawires, A V Kindrick, K B Balano,
] Tokumoto, R Aranow, C Gruta, A Harvey, J Tulsky,
N Birnbaum, B Dong, G Leoung, R H Goldschmidt
(United States)
ThPeB72o3 Nausea profile of HIV+ persons beginning
antiretroviral therapy: a prospective time series
study
N R Reynolds, ] L Neidig (United States)
ThPeB72o4 Rates of toxicity and treatment modification of
HAART in patients with primary HIV infection
B P Sabundayo, ] H McArthur, S] Langan,
J Gallant, ] B Margolick (United States)
ThPeB72o5 The rate of disease progression and the effect of
treatment in people with haemophilia and HIV
infection
M A Khanam', L Ashton2, R Garcia2, ] Learmont2
('Bangladesh; 2 Australia)
ThPeB72o6 Untreated subjects followed from HIV primary
infection (PI) differ from those treated with HAART
with respect to persistence of the hierarchy of HIV
peptide recognition longitudinally
G Alter CM Tsoukas, ] P Routy, D Rouleau,
R Thomas, ] G Baril, P Cote, R Sekaly, N F Bernard
(Canada)
ThPeB72o7 Is simplification to triple antiretroviral therapy
after viral suppression with quadruple therapy
initiated at the time of primary infection
associated with increased low-level viral
breakthrough?
S Kinloch', L Lampe', G ]anossy', A Phillips',
D Cooper, L Perrin3, ] Andersson4, B Hoens,
H Mcdade', L Goh' ('United Kingdom; 2Australia;
3Switzerland; 4Sweden; SFrance)
ThPeB72o8 Factors contributing to reported high defaulter
rates among patients on TB treatments

Y Taidhi, S Kapere, R Serunkuma, M Sonko,
D Magezi (Uganda)

ThPeB72o9 Prevalence of resistance associated mutations in
antiretroviral drug naive Zambians infected with
subtype CH IV-i
R Handema, H Terunuma', F Kasolo2, H Kasai',
A Yamashita', D Xuewen', N Yamamoto', M Ito'
('Japan; 2Zambia)
ThPeB7210 Early experience with baseline HIV genotyping
D A W Daniel Warner MD (United States)
ThPeB7211 The impact of transmitted drug resistance on
time to CD4 350 cells/ml
K Porter, D Pillay, on behalf of UK Register of HIV
Seroconverters (United Kingdom)
ThPeB7212 Incidence of HIV-1 Drug Resistance (DR) from
1996 to 2001 in the Montreal Primary HIV
Infection Cohort
JPRoutyj, B Brenner, S Bruce, B Spira, M Legault,
D Moisi, D Rouleau, P Cote, R Thomas,
R G Lalonde, R Leblanc, M Petrella, R P Sekaly,
M Wainberg (Canada)
ThPeB7213 Prevalence of HIV-1 drug resistance mutations in
patients with primary HIV-1 infection (PHI) in
Barcelona (Spain)
M Arnedo, ] M Mir6, T Pumarola, C Gil,
X Claramonte, A del Rfo, ] Joseph, M Plana,
J L Blanco, F Garcia, E Martfnez, ] M Malloles,
T Gallart, ] M Gatell (Spain)
ThPeB7214 Transmission of drug resistant virus in primary
HIV-1 infection
M Brad S Fidler, ] Clarke, ] Weber
(United Kingdom)
ThPeB7215 Prevalence of genotypic antiretroviral drugresistant HIV-1 strains among naive children
A Afonso', ES Machado', ]S Lambert2, E Caride',
S M Cunha', R H Oliveira', A Tanuri'
('Brazil; 2United States)
ThPeB7216 Brazilian network for drug resistance
surveillance: results from the first national survey
A Tanuri, MA Soares, R M Brindeiro, R S Diaz,
L ]Costa, E C Sabino, N Gaburo Jr., L Brigido,
R Rodrigues, I L Pires, F Esperanza,
M M Morgado, J Fernandez, C Lauria, M C Dantas,
P R Teixeira (Brazil)
ThPeB7217 The pattern of HIV-1 primary resistance in Italy
after HAART therapy
M Violin', A Cozzi-LeprP, R Piscopo',
A Giacometti', C F Perno', A d'Arminio Monforte,
C Balotta' ('Iltaly; 2United Kingdom)
ThPeB7218 Comparison of absolute CD4 and CD8 T-cell
counts, multi-platform versus single-platform
methods
G D Cross, J H Handsfield (United States)
ThPeB7219 Pediatric HIV-1 in Kenya: Predictors of early mortality
E Obimbo', D A Mbori-Ngacha, PA Otieno',
R K Bosire', ]I Bchieng', C Farquhar, ] K Kreiss2,
G Clohn-Stewart2 ('Kenya; 2United States)
ThPeB722o The Spectrum of opportunistic infections in HIVAIDS patients in a tertiary care hospital in New
Delhi, India
S K Agarwal, A Makhija, S Anuradha, N P Singh,
U K Baveja (India)
ThPeB7221 Women of Coastal Andha (India) are nonprogressors of HIV disease - A cohort study
KS R Dr.Kutikuppala, R D Pilli, M Gurulaxmi
(India)
ThPeB7222 Polymorphisms of coreceptor-related genes
associated with HIV-1 disease progression and
infection in Japanese hemophiliacs

X W Deng H Terunuma, R Handema, H Hanabusa,
M Taki, H Kasai, A Yamashita, T Shioda, M Ito,
] Mimaya (Japan)

Thursday

220 Final Program